PhRMApedia Press Room
PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases. PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.
WASHINGTON, D.C. (August 18, 2016) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Allyson Funk provided the following statement in reaction the Centers for Medicare & Medicaid Services (CMS) Part D data release:
“The Medicare Part D cost data released today are misleading and do not accurately represent what Medicare pays for prescription drugs. The data exclude the substantial discounts and rebates negotiated directly between manufacturers and Part D plans to deliver value to beneficiaries.
WASHINGTON, D.C. (July 15, 2016) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement on today’s release of the Prescription Drug User Fee Act (PDUFA) VI performance goals letter:
Washington, DC (July 15, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today three biopharmaceutical research companies joined the association as members and two transitioned from research associates to full members.
Washington, DC (July 12, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced James C. Stansel will join the organization as executive vice president and general counsel. He will oversee the organization’s legal department beginning August 1, 2016.
Washington, DC (June 30, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Brian Toohey will join the association as senior vice president for international advocacy. Toohey returns to PhRMA on July 11, 2016.
WASHINGTON (June 10, 2016) — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President, International, Jay Taylor, issued the following statement on Colombia’s issuance of a Declaration of Public Interest:
“We are very disappointed that Colombia has decided to issue a Declaration of Public Interest as a prelude to imposing additional price cuts on a proven cancer medicine.
Washington, D.C. (May 17, 2016) — The biopharmaceutical industry supported nearly 854,000 direct jobs and another 3.5 million jobs and more than $1.2 trillion in economic output in the United States in 2014, according to new research prepared for the Pharmaceutical Research and Manufacturers of America (PhRMA) by TEConomy Partners, LLC. The report, which analyzed state and national data across the large-scale biopharmaceutical sector supply chain, highlights how the discovery, development and delivery of innovative medicines translate into higher-wage jobs, increased tax revenue and greater economic output in our local communities
WASHINGTON (12 de mayo, 2016) – Las compañías miembros de la Empresa de Investigación y Fabricantes de Farmacéutica de América (PhRMA) invirtieron aproximadamente $58,8 billones en investigación y desarrollo (I&D) en el año 2015, un aumento del 10,3 por ciento sobre el 2014.
WASHINGTON (May 12, 2016) — Pharmaceutical Research and Manufacturers of America’s (PhRMA) member companies invested an estimated $58.8 billion in research and development (R&D) in 2015, up 10.3 percent from 2014. New R&D data based on findings from the 2016 PhRMA annual member survey released today in the 2016 Biopharmaceutical Research Industry Profile and corresponding industry chart pack, Biopharmaceuticals In Perspective, highlight the wide-reaching impact of PhRMA member companies on the economy and biopharmaceutical innovation.
WASHINGTON (May 9, 2016) — America’s biopharmaceutical research companies are currently developing more than 560 medicines for patients with rare diseases, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) and The ALS Association. Medicines in development include therapies for multiple myeloma, cystic fibrosis, amyotrophic lateral sclerosis (ALS) and enzyme deficiency disorders, providing treatment options for patients that had few or no treatment options before.
Washington, DC (May 2, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Lauren Levinson joined the organization as vice president of communications.
Levinson will help craft the association’s communications strategy and public positioning and will manage a team responsible for executive visibility, rapid response, proactive media outreach and a number of high-profile public affairs campaigns. She will report to Robert Zirkelbach, senior vice president of communications.
WASHINGTON, D.C. (April 27, 2016) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President Jay Taylor issued the following statement today:
“PhRMA members appreciate the continuing work of the Office of the U.S. Trade Representative (USTR), the Departments of State and Commerce, U.S. overseas missions and others to establish and ensure full compliance with strong rules protecting patents and other intellectual property rights abroad. Special 301 is an essential tool to bring high-level attention to intellectual property and market access challenges in overseas markets that are harming American innovators, patients, and workers.
Washington, D.C. (April 25, 2016) — Pharmaceutical Research and Manufacturers of America (PhRMA) senior vice president Robert Zirkelbach today released the following statement in response to the Campaign for Sustainable Rx Pricing’s proposals:
“These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and insurance companies to make one-size-fits-all treatment decisions for patients.
Washington, D.C. (April 7, 2016) Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on recommendations voted on at MedPAC’s April meeting:
“PhRMA strongly opposes the sweeping new Medicare Part D recommendations approved by MedPAC earlier today. Taken together, these recommendations will significantly harm beneficiaries by eroding coverage and protections for some of the most vulnerable enrollees in the program. MedPAC’s vote also ignores broad stakeholder concerns raised in response to these proposals.
Washington, D.C. (March 17, 2016) -- Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on the FDA and NIH Workforce Authorities Modernization Act:
“To fulfill its central mission of protecting public health by fostering timely patient access to safe and effective new medicines, the U.S. Food and Drug Administration (FDA) needs the ability to hire and retain sufficient numbers and types of technical and scientific experts to efficiently conduct reviews of human drug applications.
“While we are still reviewing the language in the Senate bill, we support enhanced hiring authority at the FDA as well as the National Institutes of Health (NIH).